Head to Head Contrast: Anika Therapeutics (NASDAQ:ANIK) & Argos Therapeutics (ARGS)

Anika Therapeutics (NASDAQ: ANIK) and Argos Therapeutics (NASDAQ:ARGS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.

Valuation & Earnings

This table compares Anika Therapeutics and Argos Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anika Therapeutics $103.38 million 7.97 $32.54 million $2.12 26.50
Argos Therapeutics $950,000.00 15.29 -$53.02 million ($1.12) -0.15

Anika Therapeutics has higher revenue and earnings than Argos Therapeutics. Argos Therapeutics is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Anika Therapeutics and Argos Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anika Therapeutics 0 0 1 0 3.00
Argos Therapeutics 0 3 0 0 2.00

Anika Therapeutics currently has a consensus price target of $57.00, indicating a potential upside of 1.46%. Argos Therapeutics has a consensus price target of $1.20, indicating a potential upside of 625.95%. Given Argos Therapeutics’ higher possible upside, analysts clearly believe Argos Therapeutics is more favorable than Anika Therapeutics.

Insider and Institutional Ownership

84.9% of Anika Therapeutics shares are held by institutional investors. Comparatively, 18.4% of Argos Therapeutics shares are held by institutional investors. 6.6% of Anika Therapeutics shares are held by company insiders. Comparatively, 28.2% of Argos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Anika Therapeutics and Argos Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anika Therapeutics 28.23% 13.40% 12.41%
Argos Therapeutics -13,750.64% N/A -120.95%

Risk & Volatility

Anika Therapeutics has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Argos Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.

Summary

Anika Therapeutics beats Argos Therapeutics on 11 of the 14 factors compared between the two stocks.

About Anika Therapeutics

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.

About Argos Therapeutics

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply